Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.
You may also be interested in...
Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
NICE Clears Pradaxa For Stroke Prevention, Rejects Appeal By NHS Budget Holders
Following a failed appeal by regional NHS payers worried about its cost, Boehringer Ingelheim's Pradaxa is finally recommended by the U.K.'s cost watchdog, NICE, for preventing stroke associated with atrial fibrillation.
NICE Again Rejects Xarelto, This Time In DVT Indications
U.K. cost watchdog NICE asks for further data on use of Bayer's Xarelto for the treatment and prevention of deep vein thrombosis, having made similar demands at the start of the year on its use in atrial fibrillation.